Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 10 Mar 2023
Today's top stories include: Nine-year cap to complete MBBS, elective-based credits offered in NMC letter Students enrolled in...
Read Full NewsA phase 2a trial showed that NLX-112 was safe and well tolerated in patients with Parkinson disease, while also reducing levodopa-induced dyskinesia and motor symptoms, supporting further clinical development.
AskBio noted that AB-1009 also recently received fast track and orphan drug designations from the FDA.
Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and Older
1.
Males with early-onset colorectal cancer are at risk, according to a study.
2.
For elderly, unfit patients, the all-oral AML regimen shows promise.
3.
Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer
4.
Detecting invasive nodules could be key to preventing unnecessary pancreatic cancer surgery
5.
Neural networks and label-free microscopy enable accurate detection of pancreatic tumors
1.
Beyond the Standard: Personalized Cancer Vaccines and the Dawn of a New Era in Pediatric Oncology
2.
Everything You Need To Know About Trichelemmal Cysts: Symptoms, Causes, Diagnosis And Treatment
3.
Everything You Need to Know About CA 19-9 and Cancer Diagnosis
4.
Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment
5.
Priming Agents: A Novel Approach to Enhancing Cell-Free DNA Detection in Liquid Biopsies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
2.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge